e-learning
resources
London 2016
Wednesday, 07.09.2016
Novel mechanisms and treatment modalities in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab, airway obstruction and remodeling
Michela Maria Bellocchia (Turin, Italy), Michela Maria Bellocchia, Renza Ambrosanio, Filippo Patrucco, Giulia Verri, Lorena Mercante, Monica Boita, Giuseppe Tabbbia, Alessio Mattei, Paolo Solidoro, Caterina Bucca
Source:
International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Session:
Novel mechanisms and treatment modalities in asthma
Session type:
Poster Discussion
Number:
4901
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Michela Maria Bellocchia (Turin, Italy), Michela Maria Bellocchia, Renza Ambrosanio, Filippo Patrucco, Giulia Verri, Lorena Mercante, Monica Boita, Giuseppe Tabbbia, Alessio Mattei, Paolo Solidoro, Caterina Bucca. Omalizumab, airway obstruction and remodeling. Eur Respir J 2016; 48: Suppl. 60, 4901
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Airway remodelling in the U-BIOPRED severe asthma cohort
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Modulation of inflammation by benralizumab in eosinophilic airway disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Airway remodeling and eosinophilic asthma
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Characterisation of asthma patients with persistent airflow obstruction
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016
Features of inflammation in the asthma patients with osmotic airway hyperresponsiveness
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
Airway hyperresponsiveness (AHR) of small airways assessed by impulse oscillation (IOS) in adult asthma
Source: International Congress 2015 – Asthma mechanisms and management
Year: 2015
Syk mediates airway hyper-responsiveness and airway remodeling in a chronic mouse model of house dust mite induced allergic airways disease
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013
Risk factors for airway remodeling and irreversible airway obstruction in Asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Small airway abnormalities in elderly asthmatics with fixed airflow obstruction vs. COPD: High-resolution CT and pulmonary functions
Source: International Congress 2014 – Non inflammatory monitoring of airway diseases
Year: 2014
The effect of oligomeric proanthocyanidin on airway microenvironment in asthma
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
The effect of inhaled ciclesonide on airway blood flow
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Autoreactivity and inflammatory phenotypes in patients with COPD and bronchial asthma
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Association between airway inflammation, airway remodelling and physiological changes in asthma
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma.
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Association between cardio-ankle vascular index (CAVI) and chronic airway obstruction in asthma
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
Can forced oscillation technique parameters predict airway hyperresponsiveness to histamine?
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept